Editas Medicine, Inc.

EDIT

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US246 employeeseditasmedicine.com

$2.68

+0.07(2.68%)

Mkt Cap $262M

$0.98

$4.15

52-Week Range

At a Glance

AI-generated

Editas Medicine, Inc.

Revenue breakdown: Reportable Segment (100%).

8-K

Editas Medicine announced that the U.S. Patent and Trademark Office reaffirmed a prior decision favoring the Broad Institute in a CRISPR/Cas9 patent interference case on March 26, 2026. This outcome reinforces the company's intellectual property foundation for developing CRISPR/Cas9-based medicines, including EDIT-401.

$262M

Market Cap

$45M

Revenue

-$177M

Net Income

Employees246

Fundamentals

How The Business Makes Money

Revenue by Segment

Reportable Segment100%($73M)

Activity

What Changed Recently

Financial Results

Mar 8, 2026

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “

Regulation FD

Mar 26, 2026

in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “

Peer Companies

Company	Price	Change	Market Cap	P/E
CAPRCapricor Therapeutics, In...	$32.12	+6.62%	$1.5B	-14.0
ALLOAllogene Therapeutics, In...	$2.50	-2.54%	$608M	-2.8
LYELLyell Immunopharma, Inc.	$21.20	+1.90%	$494M	-1.2
AVIRAtea Pharmaceuticals, Inc...	$5.75	+1.86%	$459M	-2.7
VNDAVanda Pharmaceuticals Inc...	$6.99	-1.20%	$413M	-1.9
KYTXKyverna Therapeutics, Inc...	$8.85	+0.86%	$387M	-2.1
CABACabaletta Bio, Inc.	$2.97	+10.82%	$286M	-1.2
VYGRVoyager Therapeutics, Inc...	$3.94	-1.13%	$235M	-1.9

Analyst View

Company Profile

CIK0001650664

ISINUS28106W1036

CUSIP28106W103

Phone617 401 9000

Address11 Hurley Street, Cambridge, MA, 02141, US

SEC EDGAR